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Abnormal accumulation and aggregation of amyloid--peptide (A) eventually lead to the
formation and cerebral deposition of amyloid plaques, the major pathological hallmark in
Alzheimer’s disease (AD). Oleuropein (OE), an Olea europaea L. derived polyphenol, exhibits a
broad range of pharmacological properties, such as antioxidant, anti-inflammatory, and
antiatherogenic, which could serve as combative mechanisms against several reported
pathways involved in the pathophysiology of AD. The reported noncovalent interaction
between A and OE could imply a potential antiamyloidogenic role of the latter on the former
via stabilization of its structure and prevention of the adaptation of a toxic -sheet conforma-
tion. The established -sheet conformation of the A hydrophobic carboxy-terminal region
and the dependence of its toxicity and aggregational propensity on its secondary structure
make the determination of the binding site between A and OE highly important for assessing
the role of the interaction. In this study, two different proteolytic digestion protocols, in
conjunction with high-sensitivity electrospray ionization mass spectrometric analysis of the
resulting peptide fragments, were used to determine the noncovalent binding site of OE on A
and revealed the critical regions for the interaction. (J Am Soc Mass Spectrom 2008, 19,
1078–1085) © 2008 American Society for Mass SpectrometryAmyloid--peptide (A) is a 39–43 amino acidpeptide characterized by high aggregationalpropensity and neurotoxicity. It is the central
component of the senile plaques in Alzheimer disease
(AD) brain [1] and its aggregational properties depend
on both the peptide concentration and conformation, as
well as on the solution conditions and pH [2, 3]. It has
been reported that reduction of the A production, by
controlling the cleavage of the larger transmembrane
amyloid precursor protein (APP), or inhibition of its
aggregation by using small molecules, which may in-
teract noncovalently with A and stabilize its structure,
could serve as preventive or therapeutic approaches
against AD [4]. In general, interruption of noncovalent
interactions between protein and peptides, or even
more between proteins/peptides and ligands can cause
abnormalities, which often lead to diseases [5]. One
interaction of this kind has been established between
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doi:10.1016/j.jasms.2008.03.011the Olea europaea derived bioactive compound, oleuro-
pein (OE), and A by means of electrospray ionization
mass spectrometry (ESI-MS) [6]. This interaction could
prove potent in inhibiting its aggregation.
OE is a polyphenol extracted from the fruits and
leaves of Olea europaea L. and possesses a wide range of
pharmacological properties, such as antioxidant [7–9],
anti-inflammatory [10, 11], antiatherogenic [12–14], an-
tibacterial [15–17], and anticancer [18, 19]. Moreover,
OE and its metabolites have been shown to be potent
against contemporary diseases, such as HIV [20, 21] and
osteoporosis [22, 23]. Interestingly, in vitro [24] and
epidemiological [25] studies demonstrated the positive
impact of polyphenols on the onset of age-related
disorders, such as dementia [26, 27].
It is regarded that the pathophysiology of AD is
tangled and many theories have been proposed to
illumine its mechanism. Free radical reactions and
oxidative stress [28, 29], as well as unregulated immune
response [30, 31], are believed to be key factors for the
pathogenesis of AD, whereas recent reports suggested a
link between heart disease, hypercholesterolemia, and
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anti-inflammatory, and antiatherogenic properties of OE
may offer a multistage approach against the diverse
mechanisms, which are inherent to AD. This, in conjunc-
tion with the ability of OE to interact with A, thus
blocking the peptide in a nontoxic conformation and
inhibiting its aggregation, may introduce an ideal regime
against its neurotoxicity. However, natural extracts and
plants containing antioxidants and phytoestrogens have
been involved in the management of cognitive disorders
[26], such as AD, and against A-induced toxicity.
Structural and conformational alterations underlying
the peptide fibril formation is a multistep reaction
involving oligomeric and protofibrillar intermediates
[34]. It has been reported that distinct regions of the
peptide are responsible for its fibrillation and its subse-
quent toxicity, especially the carboxy-terminal hydropho-
bic segment [35]. This region adopts an intermolecular
-sheet conformation crucial for the oligomerization cas-
cade. It is evident that determination of the noncovalent
binding site between OE and A would not only
increase our understanding of complexation, but would
also shed some light into the fibrillization reaction
mechanism. Therefore, the goal of the present study is
the actual localization of the interaction site between the
ligand and the peptide. This is accomplished by enzy-
matic mapping of the noncovalent complex using two
different proteolytic enzymes and the enhanced sensi-
tivity and mass accuracy provided by ESI Fourier
transform ion cyclotron (FT-ICR) MS, thus allowing the
precise assignment of the binding site. The two proteo-
lytic enzymes used were trypsin and Glu-C, to produce
peptide fragments and thus establish the critical pep-
tide regions for the interaction. ESI provides gentle
conditions for the transfer of fragile noncovalent inter-
actions in the gas phase and allows their detection by
MS, which is optimal for following real-time interac-
tions and probing potential intermediates.
Experimental
Sample Preparation
Noncovalent complex monitoring. A 150 L sample of a
freshly prepared -amyloid peptide, A (1–40) (Bachem
AG, Bubendorf, Switzerland) solution 100  (Mr
monoisotopic: 4327.15) in deionized water was added to
150 L of an equimolar solution of OE [Mr monoiso-
topic: 540.18 isolated from olive leaves of Olea europaea
(var. koroneiki), according to a previously described
procedure [36] with greater than 99% purity, as as-
sessed by NMR analysis in 1 mM ammonium acetate
(Merck, Darmstad, Germany)-acetic acid (Pancreac,
Barcelona, Spain) 0.5% buffer solution(pH 3).
Enzymatic digestion for mapping analysis. Tryptic and
Glu-C enzymatic mapping was used to study the inter-
action site between A peptide and OE. The A peptide
and its mixtures with the ligand were dissolved in 25mM ammonium bicarbonate (Merck) and the pH of the
solution was adjusted to 8.0 with dilute aqueous solu-
tion of ammonium hydroxide. Then trypsin (Roche,
Mannheim, Germany) or Glu-C (Sigma, St. Louis, MO,
USA) was added in 1:100 M ratio (or 5% wt). The
enzymatic reaction was carried out at 37 °C and
quenched after 14 h by adding 2.5% acetic acid and
deep-freezing of the samples. Similarly, solutions of
trypsin and Glu-C were incubated, analyzed, and used
as blank samples. All solvents used were of analytical-
grade purity. Post addition of OE to already digested
A was also performed and the samples were then
analyzed by ESI-MS.
Sample desalting. The peptide solutions, the resulting
mixtures with OE, and peptide digests thereof were
desalted on a ZipTipC18 pipette tip (Millipore, Billerica,
MA, USA) before MS analysis using the following
protocol. The tip was first wetted with 3  10 L
aqueous acetonitrile solution 50% and then equilibrated
with 3  10 L 1% aqueous acetic acid solution. The
digest was adsorbed onto the reversed-phase media by
30 repeated cycles of sample loading. The tip was
washed with 3  10 L 1% acetic acid. Finally, the
desalted digests were eluted with 10 L of 50% aceto-
nitrile in 1% aqueous acetic acid. This procedure was
repeated three times, resulting in a total volume of 30
L of the eluate. After the desalting, the eluates were
directly subjected to ESI FT-ICR MS analysis.
Mass Spectrometry
All mass spectra were acquired using a Bruker Dalton-
ics (Billerica) BioAPEX-94e superconducting 9.4 T FT-
ICR mass spectrometer [37] in broadband mode. A
home-built apparatus controlled the direct infusion of
the samples. Helium gas at a pressure of 1.3 bar was
used to infuse the sample through a 30 cm fused-silica
capillary with a 50 m inner diameter. One end of the
capillary was inserted into the sample and the other
one, coated by a conductive graphite/polymer layer of
“Black Dust” [38], was connected to ground functioning
as a sheathless electrospray needle. No sheath flow or
nebulizing gas was used. The flow rate was about 4
nL/min. The ion source was coupled to an Analytica
atmosphere–vacuum interface (Analytica, Branford, CT,
USA) and a potential difference of 2.0–3.0 kV was applied
across a distance of 3–5 mm between the spraying needle
and the inlet capillary. Typically, 512K data points were
acquired, adding a minimum of 128 spectra.
Results and Discussion
The high resolving power of ESI FT-ICR MS was used
to identify the binding site of the A-OE noncovalent
complex. ESI offers a gentle ionization method optimal
for maintaining fragile interactions, such as noncova-
lent complexes. In addition, the enhanced sensitivity
and mass accuracy of FT-ICR make it ideal for conduct-
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binding site between the ligand and the peptide.
The reported conservation of the A-OE noncovalent
interaction even in high content of organic cosolvent
(75% of MeOH) [6] allows the SPE (ZipTipc18) purifica-
tion of the samples before analysis, and also the use of
sheathless ESI interface coupled to the FT-ICR analyzer.
The increased FT-ICR sensitivity permitted the detec-
tion of low-abundance species, even though the ESI
conditions are “harder” than those previously used in a
triple quadrupole analyzer [6]. Indeed, the A-OE non-
covalent interaction was confirmed using ESI FT-ICR
MS and novel interactions were revealed as well.
ESI-MS analysis of the A-OE samples results in
“bell-shaped” distributions of multiply charged ions
corresponding to A peptide, its oxidized AMet35(O)
and superoxidized AMet35(O2) forms, and their cor-
responding complexes with OE in various stoichiome-
tries. The noncovalent interaction between OE and
intact A (1–40) (Figure 1), as well as with its oxidized
form AMet35(O), possessing an 1:1 stoichiometry, was
verified under these conditions. Deconvolution of the
spectra gave rise to 4327.19, 4343.26, 4867.27, and 4883.49
monoisotopic mass values, which correlate with the theo-
retical values 4327.16, 4343.14, 4867.34, and 4883.33 for A,
AMet35(O), A-OE, and AMet35(O)-OE (1:1), respec-
Figure 1. ESI mass spectrum of amyloid--pe
molecular ratio, acquired by a 9.4 T FT-ICR
correspond to (a) the 5 charged ion of A (1–4
of the A-OE noncovalent complex at m/z 974.46.tively. However, the enhanced sensitivity and resolu-
tion of FT-ICR MS enabled the detection of A:OE
noncovalent complexes with higher stoichiometries (1:
2), albeit at a much lower abundance. The methodology
used also allowed the detection of low-abundance oxi-
dized forms of A [i.e., AMet35(O) and AMet35(O2)]
and the OE 1:1 noncovalent interactions thereof (Table
1). The observation of these complexes shows the ex-
ceptional importance for an antioxidant such as OE,
because it can bind not only to A and prevent its
oxidation and subsequent aggregation, but also to al-
ready oxidized species and stop their aggressive pro-
gression. Moreover, OE can interact with A reactive
oxygen species (ROS), deactivate them, and thus protect
against their deleterious effect. The theoretical monoiso-
topic mass values of all the aforementioned species as
well as the observed monoisotopic mass values de-
tected are shown in Table 1.
The soft ESI conditions used in this study combined
with the analytical strength of the FT-ICR mass ana-
lyzer enabled the detection of noncovalent complexes
between A and OE in stoichiometries 1:1 and 1:2
(Table 1). However, the relative intensity of these spe-
cies varied, with the 1:1 A:OE noncovalent complex
(Figure 1) being the most abundant and the 1:2 A:OE
the least abundant. It has been previously shown from
(1–40) in a mixture with oleuropein in a 1:1
yzer. The magnified regions of the spectrum
ptide at m/z 866.45 and (b) the 5 charged ionptide
anal
0) pe
E non
E
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not artifacts of the ESI process. The fact that more than
one molecules of OE can be bound to A may indicate
a protective role of OE against aggregation. The binding
of OE molecules along the peptide’s backbone may lock
A’s conformation, thus preventing other molecules of
A to form polymeric species.
Establishment of the specific site of interaction be-
tween OE and A (1–40) was carried out by using
trypsin and Glu-C proteolytic enzymes to gain comple-
mentary information on A sequence. These mapping
studies are important, in identifying which region of the
peptide interacts with the ligand, and determine whether
the hydrophobic segment of A is involved, which is
responsible for the -sheet intermolecular conformation
in aqueous solutions and, consequently, for the neuro-
toxicity of the peptide. Trypsin cleaves the peptide in
almost equal segments of 11–12 residues, except from
the first [1–5] fragment. Glu-C cleaves the peptide in
fragments of various lengths, but in between the three
first fragments derived from the tryptic digestion (Table
2). Moreover, two different approaches were attempted:
addition of OE to A peptide before digestion and
addition of OE to already digested A peptide. This
methodology could prove whether A’ s folding is critical
for the binding, as well as whether certain residues of A
are critical for the interaction.
Table 1. Theoretical and observed mass values of A (1–40) pe
complexes with oleuropein (OE)a
Monoisotopic
mass v
Species Mr (5
Peptide
A (1–40) 4327.16 866
Oxidized peptide
AMet35(O) 4343.14 869
AMet35(O)2 4359.14 872
Noncovalent complexes with OE
A (1–40)-OE 4867.34 974
A (1–40)-2OE 5407.52 1082
AMet35(O)-OE 4883.33 977
AMet35(O)2-OE 4899.32 980
aThe observed mass and m/z values of the detected A species and O
Table 2. Theoretical and observed mass values of A (1–40) pe
oleuropein (OE) following enzymatic digestion with trypsin and
Peptide fragments Mon
nzyme # sequence
Trypsin [1–5] DAEFR 6
[6–16] HDSGYEVHHQK 13
[17–28] LVFFAEDVGSNK 13
[29–40] GAIIGLMVGGVV 10
Glu-C [1–3] DAE 3
[4–11] FRHDSGYE 10
[12–22] VHHQKLVFFAE 13
[23–40] DVGSNKGAIIGLMVGGVV 1684.9Digestion with trypsin yielded the four expected A
fragments: [1–5], [6–16], [17–28], and [29–40] following
cleavage after arginine (R) or lysine (K) residues (Table
2), as well as partially cleaved fragments (Table 3). The
soft ESI ionization also enabled the detection of nonco-
valent interactions between sequential and nonsequen-
tial fragments. Oxidized forms of fragments containing
not only the Met35 residue, but also the additional
signals corresponding to fragments derived from weak
chymotryptic activity (inherent property of trypsin so-
lutions) were also detected in the mass spectra.
Noncovalent interactions of peptide fragments with
OE, added before digestion, were detected for the [17–28]
fragment of A (Figure 2) and the partially cleaved
peptide fragments [6–28] and [6–40]. In addition, non-
covalent complexes of OE with the [5–19] fragment,
derived from the chymotryptic activity of the enzyme,
was also detected.
When OE was added into already digested A
samples with trypsin (Table 3), signals corresponding
to the following noncovalent interactions were de-
tected: [(17–28)OE], [(1–16)OE], [(6 –28)OE], [(6 –
40)OE], and [(17–40)OE]. Oxidized and superoxi-
dized forms of A tryptic fragments [(1–16) (29–
40)OOE] and [(1–16) (29–40)O2OE] were
found to interact noncovalently with OE, as well as
with the chymotryptic A fragment [5–19].
, its oxidized variants, and their potential noncovalent
retical Monoisotopic observed
mass values
(4) Mr (5) (4)
1082.79 4327.19 866.45 1082.82
1086.79 4343.26 869.65 1086.82
1090.78 4359.34 872.88 1090.84
1217.83 4867.27 974.46 1217.88
1352.88 5407.68 — 1352.92
1221.83 4883.49 977.70 1221.91
1225.83 4899.56 980.91 1225.89
covalent complexes thereof are presented in the last three columns.
fragments and their potential noncovalent complexes with
opic Mr theoretical Monoisotopic Mr observed
A-OE A A-OE
9 1176.47 636.33 —
0 1875.78 1335.66 —
7 1864.85 1324.71 1864.88
3 1624.81 1084.69 —
2 873.30 — —
3 1549.61 1009.47 1549.68
2 1893.90 1353.74 1893.98ptide
theo
alues
)
.43
.63
.83
.47
.50
.67
.86ptide
Glu-C
oisot
A
36.2
35.6
24.6
84.6
33.1
09.4
53.72 2225.10 1684.95 —
charg
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gest yielded signals corresponding to the expected A
fragments [4–11], [12–22], and [23–40] following cleav-
Figure 2. ESI mass spectrum of amyloid--pe
molecular ratio, after enzymatic digestion with
magnified regions of the spectrum correspond
peptide at m/z 866.47, (b) the 5 charged ion of t
2 charged ion of the [17–28] A tryptic fragm
Table 3. Detected noncovalent interactions between OE and the
A-OE tryptic digest
Complete Incomplete
[17–28]OE [6–28]OE
obs: 933.44 (2) obs: 1061.85 (3)
theor: 933.42 (2) theor: 1061.81 (3)
[6–40]OE
obs: 1063.30 (4)
theor: 1061.26 (4)
aThe observed (obs) and theoretical (theor) m/z values of the multiplynoncovalent complex between [17–28] A tryptic fraage at the carboxy-terminus of glutamic acid (E) resi-
dues (Table 2), and the noncovalent complexes between
OE and the [4–11] and [12–22] A Glu-C fragments
(1–40) in a mixture with oleuropein in a 1:1
sin, acquired by a 9.4 T FT-ICR analyzer. The
) the 5 charged ion of the intact A (1–40)
-OE noncovalent complex at m/z 974.52, (c) the
t m/z 663.37, and (d) the 2 charged ion of the
tic fragments of A (1–40)a
OE addition after A tryptic digestion
Complete Incomplete
[17–28]OE [1–16]OE
obs: 933.44 (2) obs: 832.38 (3)
theor: 933.42 (2) theor: 832.35 (3)
[6–28]OE
obs: 1061.86 (3)
theor: 1061.81 (3)
[6–40]OE
obs: 1063.31 (3)
theor: 1063.26 (3)
[17–40]OE
obs: 1466.76 (2)
theor: 1466.73 (2)
ed ESI signals are shown.ptide
tryp
to (a
he A
ent atrypgment and oleuropein at m/z 933.48.
pein
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cleaved peptide fragments [4–40] and [12–40] (Table 4),
and the added A fragments [(4–11)(12–22)] and [(12–
22)(23–40)] were also observed.
Figure 3. ESI mass spectrum of amyloid--pe
molecular ratio, after enzymatic digestion with
magnified regions of the spectrum correspond to
at m/z 866.47, (b) the 5 charged ion of the A
charged ion of the [4–11] A Glu-C fragment at
complex between [4–11] A Glu-C fragment an
the [12–22] A Glu-C fragment at m/z 677.90, an
between [12–22] A Glu-C fragment and oleuro
Table 4. Detected noncovalent interactions between OE and the
A-OE Glu-C digest
Complete Incomplete
[4–11]OE [4–40]OE
obs: 775.85 (2) obs: 911.49 (5)
theor: 775.80 (2) theor: 911.44 (5)
obs: 1139.10 (4)
theor: 1139.06 (4)
[12–22]OE [12–40]OE
obs: 947.99 (2) obs: 1187.99 (3)
theor: 9475.95 (2) theor: 1187.94 (3)aThe observed (obs) and theoretical (theor) m/z values of the multiply chargWhen OE was added into already digested A
samples with Glu-C (Table 4), ESI signals corresponded
to the noncovalent interactions of OE with the [4–11]
A fragment, the partially cleaved peptide fragments
(1–40) in a mixture with oleuropein in a 1:1
-C, acquired by a 9.4 T FT-ICR analyzer. The
e5 charged ion of the intact A (1-40) peptide
noncovalent complex at m/z 974.52, (c) the 2
05.76, (d) the 2 charged ion of the noncovalent
uropein at m/z 775.86, (e) the 2 charged ion of
the 2 charged ion of the noncovalent complex
at m/z 948.00.
C fragments of A (1–40)a
OE addition after A Glu-C digestion
Complete Incomplete
[4–11]OE [1–11]OE
obs: 775.84 (2) obs: 933.39 (2)
theor: 775.80 (2) theor: 933.36 (2)
[12–40]OE
obs: 891.24 (4)
theor: 891.20 (4)
obs: 1187.98 (3)
theor: 1187.94 (3)ptide
Glu
(a) th
-OE
m/z 5
d ole
d (f)Glu-ed ESI signals are shown.
1084 BAZOTI ET AL. J Am Soc Mass Spectrom 2008, 19, 1078–1085[1–11] and [12–40] (Table 4), and the [(4–11)(12–22)]
added A fragments.
Processing of the aforementioned mapping data de-
rived from the two different digestion protocols utilized
in this study revealed the important regions and resi-
dues for the noncovalent interaction between A and
OE. The hydrophobic sequence [17–28] of the A pep-
tide, resulting from tryptic cleavage, appears to interact
with OE in the majority of the detected fragments
(Figure 2), either as a distinct fragment, or as part of a
longer sequence, or even as part of noncovalently
bound added fragments (Tables 2 and 3). This is further
confirmed in the ESI-MS analysis of the synthetic [12–
28] peptide fragment, where the noncovalent interac-
tion with OE is clearly observed. Comparison between
the interacting tryptic and Glu-C peptide fragments
indicates that the sequence [17–22] is critical for the
interaction with OE (Tables 2 and 4). Furthermore, the
[4–11] and [12–22] sequences of the A peptide derived
from Glu-C digestion interact with OE, either as a
distinct fragment (Figure 3) or as part of a longer
sequence. The aforementioned data suggest that the
amino acid segments [17–28], [4–11], and [12–22] of the
A peptide (Figures 2 and 3) are responsible for its
noncovalent complexation with OE. The interaction of
the chymotryptic fragment [5–19] with OE also corrob-
orates the aforementioned indication. Thus, possibly
two distinct molecules of OE can be bound to A
peptide, confirming the previously detected (1:2) stoi-
chiometry of the A-OE noncovalent complex.
On the contrary, fewer interactions were detected
between the ligand and the peptide fragments when OE
was added into already digested A samples (Tables 3
and 4). This is an indication that the detected interac-
tions are specific and not attributed to random aggre-
gation in the gas phase. It also demonstrates that the
folding of A is critical for the binding and some kind
of structural pocket is formed, where OE is fitted.
The fact that Glu-C proved to be more efficient than
trypsin in cleaving the A-OE complex (as shown by
the higher relative signal intensity of the relevant spe-
cies) may yield some information about the site of the
OE interaction. Possibly OE’s binding site contains the
target amino acids for tryptic cleavage, thus preventing
trypsin from cleaving the peptide. Moreover, the topol-
ogy of binding was confirmed by a thorough study of
the interaction between 15N labeled A and OE using
1D and 2D homo- and heteronuclear NMR spectros-
copy. NMR data show that the polar N-terminal frag-
ments Ala2-Glu11 and Leu17-Ala21 undergo substan-
tial chemical shift variations when the A peptide is
titrated with OE [39] (Supplementary material, which
can be found in the electronic version of this article).
Indeed, the polar group of the OE substrate, such as the
sugar unit, would be preferably accommodated to the
polar N-terminal fragment Ala2-Glu11, whereas the
hydrophobic Leu17-Ala21 fragment could preferen-
tially interact with hydrophobic units of OE, such as thearyl ring (the NMR data will be available as a separate
publication).
The findings of this study are important, comple-
menting several reports supporting that the [14–23] A
sequence is critical for fibrillation [40, 41], whereas the
[16–20] sequence is essential for A-A binding and
serves as a binding sequence during A polymerization
and fibril formation [42]. It has also been proposed that
structural elements in the central hydrophobic core
[17–21] and at the carboxy-terminus of A possess a key
role in controlling fibrillogenesis [34]. Moreover, it has
been reported that regions [5–8] and [17–21] of the A
hydrophobic core can prevent the neurotoxicity of
aggregated A [43].
Conclusions
This study demonstrates the multiple strength of ESI
combined with FT-ICR MS. This is an extremely pow-
erful tool for detecting noncovalent interactions of
biomolecules with natural products, even if they are
present in small amounts, allowing dynamic determi-
nation of all species present in the samples. The pre-
sented data indicate that OE interacts noncovalently
with A and its oxidized forms, with A amino acid
segments [4–11], [12–22], and [17–28] being implicated
in the interaction with OE.
This information on the binding site derived from
two different digestion protocols could be used to
reveal the specific residues that are involved in A’s
interaction and fibrillation process. The plant-derived
phytochemical under study may serve as a potential
aggregation inhibitor of A and act as protective or
even more therapeutic agent against AD. Nevertheless,
further confirmatory experiments were conducted with
complementary instrumentation, such as 1D and 2D
NMR spectroscopy. This information along with in-
tended tandem MS experiments of the A-OE proteo-
lytic fragments will shed light into the topology of the
interaction. The presented ESI-MS-based methodology
may also serve as a screening tool for evaluating new
structural analogues of OE and facilitate the design of
novel potential anti-amyloidogenic agents.
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